Gecacitinib

DRUG6 trials

Conditions

Acute Graft Versus Host Disease Grade II-IVAcute Graft vs Host DiseaseAcute Lymphoblastic LeukemiaAdvanced Solid TumorCervical CancerHSCTPh-LikeaGVHD Prophylaxis

Phase 1

Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer

RecruitingNCT07080216

Suzhou Zelgen Biopharmaceuticals Co.,LtdCervical Cancer

Start: 2025-09-23End: 2027-12-31Target: 120Updated: 2026-01-05

Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors

Not yet recruitingNCT07142837

Suzhou Zelgen Biopharmaceuticals Co.,LtdAdvanced Solid Tumor

Start: 2025-09-30End: 2027-12-31Target: 153Updated: 2025-08-27

Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD).

Not yet recruitingNCT07476872

Institute of Hematology & Blood Diseases Hospital, ChinacGVHD, HSCT

Start: 2026-03-16End: 2028-11-01Target: 33Updated: 2026-03-17

Phase 2

Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy

Not yet recruitingNCT07197112

Ruijin HospitalAcute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease

Start: 2025-10-01End: 2027-12-01Target: 15Updated: 2025-09-29

Unknown Phase

Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis

Not yet recruitingNCT07440654

Nanfang Hospital, Southern Medical UniversityaGVHD Prophylaxis

Start: 2026-03-01End: 2029-12-01Target: 40Updated: 2026-02-27

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

RecruitingNCT07454226

Institute of Hematology & Blood Diseases Hospital, ChinaAcute Lymphoblastic Leukemia, Ph-Like

Start: 2026-05-30End: 2030-03-01Target: 92Updated: 2026-05-13

Gecacitinib

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase